The primary outcome measure was strongly positive with 81 per cent of subjects rating Quell therapy as improving their chronic pain, the compnay announced.

According to the company, the primary outcome measure was strongly positive with 81% of subjects rating Quell therapy as improving their chronic pain.
Also, secondary outcome measures were positive with 67% of subjects reporting a reduction in use of pain medications.
Shai N. Gozani, M.D., Ph.D. President and CEO of NeuroMetrix, Inc, said that the company is pleased with these results.
“They represent the first formal evaluation of self-administered wearable intensive nerve stimulation. Quell provided substantial pain relief and improvement in quality of life measures.
The primary outcome measure was impressive with 81% of subject’s rating Quell therapy as improving their chronic pain and overall health. We were not surprised that two-thirds of the subjects reduced their use of pain medications, as we have consistently received this anecdotal feedback from Quell users over the past several months," Gozani said.
MEDINDIA




Email








